We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical Industries has received final approval from the FDA for its generic Effexor (venlafaxine hydrochloride) tablets in strengths of 25 mg, 37.5 mg, 50 mg, 75 mg, and 100 mg.
Two studies led by the U.S. Centers for Disease Control and Prevention (CDC) dealing with the effects of the December 2004 tsunami on people in affected areas of Southern Thailand have been published in The Journal of the American Medical Association.
The European Commission (EC) has granted Takeda Pharmaceutical marketing authorization for Competact, a fixed combination tablet of Actos (pioglitazone HCl) 15 mg and metformin HCl 850 mg, for Type 2 diabetes.
Singapore's Defense Medical & Environmental Research Institute and ImmuneRegen BioSciences, a U.S. firm, have announced plans to launch a study on acute melioidosis.
German pharmaceutical company Schering AG Thursday said its Betaferon drug has been approved by the Health Products and Food Branch of Health Canada, thereby extending the drug's use to now include patients in the earliest stages of multiple sclerosis, MS.
Amorfix Life Sciences Ltd., an emerging Canadian theranostics company, announced today that it has entered into a research and investment agreement with Biogen Idec of Cambridge, Massachusetts, which includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic products directed against the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS).
Astrazeneca announced that it received approval for its Pulmicort Respules for pediatric asthma infants from 6 months to under 5 years old, from the Japanese Ministry of Health, Labor and Welfare.
GlaxoSmithKline plc, GlaxoSmithKline K.K., and Sumitomo Chemical Co., Ltd., have reached an agreement whereby GlaxoSmithKline K.K. will buy all of its shares currently held by Sumitomo Chemical.